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Hypertension and obesity are known to be linked, with recent studies in mice proposing that
leptin may be mediating this effect. This regulation, however, may not extend to humans, where
a yet-to-be-identified factor is likely the underlying cause of hypertension.Figure 1. Blood Pressure in 107 Patients
with Lipodystrophy at Baseline and after 6
and 12 Months of Leptin Replacement
Blood pressure decreased significantly after
12 months (p = 0.003 for systolic and 0.02 for
diastolic).It has been shown in population studies
that hypertension correlates with
obesity. The mechanism by which this
occurs is unclear. Simonds et al.
(2014) have proposed that leptin medi-
ates the increase in blood pressure
associated with obesity. The basis for
this largely comes from mouse studies
in which leptin appears to activate
sympathetic activity through neuronal
circuits in the dorsal-medial hypothala-
mus. Simonds et al. (2014) present evi-
dence that leptin mediates an increase
in both systolic and diastolic blood
pressure as well as an increase in heart
rate in a diet-induced obesity mouse
model.
In an attempt to extend the relevance
of these mouse experiments to humans,
they cite several observations. The
major observation is that patients with
congenital leptin deficiency or leptin
receptor deficiency have low systolic
blood pressure (but normal diastolic
blood pressure) compared to weight-
matched controls. Although patients
with congenital leptin deficiency respond
to leptin therapy by increased satiety
and weight loss, there is no change
in blood pressure when leptin is given
to these individuals. Further, Simonds
et al. (2014) point out that Heymsfield
et al. (1999) did not observe an increase
in blood pressure in obese patients who
had minimal weight loss in response to
leptin therapy.
Current human data suggest that
metabolic parameters such as appetite,
body weight, triglycerides, and diabetes
control respond to leptin administra-
tion in endogenous low-leptin states(Farooqi et al., 2002; Oral et al., 2002),
but not in endogenous high-leptin states
(Heymsfield et al., 1999). The proposal
that leptin mediates the increase in
blood pressure in obesity, an endoge-
nous high-leptin state, would represent
an exception to the general idea of leptin
resistance in endogenous high-leptin
states.
Because leptin administration does
not increase blood pressure in congen-
ital leptin deficiency, we examined
another low-leptin state, lipodystrophy,
to see if leptin affects blood pressure.
Lipodystrophies are a heterogeneous
group of disorders characterized by
generalized or depot-specific absence
of subcutaneous adipose tissue and,Cellhence, low levels of the adipocyte-
derived hormone, leptin. Complications
of lipodystrophy are typical of an
extreme variant of the obesity-asso-
ciated metabolic syndrome, including
insulin resistance, diabetes, hypertrigly-
ceridemia, and fatty liver disease; these
complications are significantly improved
by leptin replacement. We examined
blood pressure in 107 patients with
lipodystrophy of various types. Patients
were enrolled in a prospective, single-
arm, open-label study evaluating effects
of recombinant human leptin (metre-
leptin) on metabolic complications of
lipodystrophy. The study was approved
by the institutional review board of
the National Institute of Diabetes
and Digestive and Kidney Diseases
(NCT00025883), and all patients or their
guardians provided written informed
consent.
Unlike patients with congenital leptin
deficiency, more than one third of
patients with lipodystrophy (mean age
24 ± 15 years) had hypertension in the
leptin-deficient state. Further, we found
no increase in either systolic or diastolic
blood pressure in these patients after
6 months of leptin treatment and small
but significant decreases in systolic and
diastolic blood pressure after 12 months
of leptin treatment at a mean dose
of 0.085 ± 0.035 mg/kg/day (Figure 1).
Under these conditions, serum leptin
levels are increased significantly by
exogenous leptin administration (Oral
et al., 2002).
These data demonstrate that mouse
models may not predict human adverse
events. Thus, hypertension was not162, July 30, 2015 ª2015 Elsevier Inc. 465
considered an adverse event in the
FDA approval of leptin as a therapy
for lipodystrophy, which is consistent
with the data presented in Figure 1.
We conclude that, because leptin
administration does not increase blood
pressure in the leptin responsive
states of congenital leptin deficiency
or lipodystrophy, it is premature to sug-
gest that leptin is the mediator of the466 Cell 162, July 30, 2015 ª2015 Elsevier Inhypertension associated with human
obesity.
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